A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer

Eur J Cancer. 1992;28A(12):1968-70. doi: 10.1016/0959-8049(92)90239-x.

Abstract

38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone. 6 patients had received prior chemotherapy for advanced disease, all with an anthracycline-containing regimen. Treatment was generally well tolerated. The most common side-effect was myelosuppression, with 1 toxic death due to leukopenia-related sepsis. 1 patient developed severe congestive heart failure 12 months from the end of therapy. 36 patients were evaluable for response. The overall response rate was 55%. Median duration of response was 8 months and median survival time was 16 months. This regimen warrants further investigations.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Cyclophosphamide / administration & dosage
  • Drug Evaluation
  • Female
  • Fluorouracil / administration & dosage
  • Heart Failure / chemically induced
  • Humans
  • Leucovorin / administration & dosage
  • Leukopenia / chemically induced
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Salvage Therapy
  • Thrombocytopenia / chemically induced

Substances

  • Cyclophosphamide
  • Mitoxantrone
  • Leucovorin
  • Fluorouracil